Abstract | OBJECTIVE:
Total hip arthroplasty (THA) is associated with substantial blood loss. The objective of present systematic review and meta-analysis is to provide evidence from randomized controlled trials (RCTs) on the efficiency and safety of administration of fibrin sealant (FS) for reducing blood loss in patients undergoing primary THA. METHODS: Potential relevant studies were identified from electronic databases including Medline, PubMed, Embase, ScienceDirect, web of science and Cochrane Library. Gray academic studies were also identified from the reference list of included studies. There was no language restriction. Pooling of data was carried out by using RevMan 5.1. RESULTS: Six randomized controlled trials (RCTs) met the inclusion criteria. Current meta-analysis indicated that there were significant differences in terms of total blood loss (MD = -153.77, 95% CI: -287.21 to -20.34, P = 0.02), postoperative hemoglobin level (MD = -0.25, 95% CI: -0.46 to -0.05, P = 0.02) and transfusion rate (RD = -0.12, 95% CI: -0.22 to -0.03, P = 0.01) between groups. No significant differences were found regarding the incidence of deep venous thrombosis (DVT) (RD = 0.00, 95% CI: -0.01to 0.01, P = 0.51) or other side effects. CONCLUSION:
|
Authors | Zhiyuan Wang, Lin Xiao, Hao Guo, Guanghui Zhao, Jianbing Ma |
Journal | International journal of surgery (London, England)
(Int J Surg)
Vol. 37
Pg. 50-57
(Jan 2017)
ISSN: 1743-9159 [Electronic] United States |
PMID | 27939268
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | Copyright © 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Fibrin Tissue Adhesive
- Hemoglobins
- Hemostatics
|
Topics |
- Arthroplasty, Replacement, Hip
- Blood Loss, Surgical
(prevention & control)
- Blood Transfusion
(statistics & numerical data)
- Fibrin Tissue Adhesive
(therapeutic use)
- Hemoglobins
(analysis)
- Hemostatics
(therapeutic use)
- Humans
- Postoperative Period
- Randomized Controlled Trials as Topic
|